DMPA

A Roadmap for Results - Understanding the ECHO Trial Findings

Results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study were released at a session at the 9th South African AIDS Conference (SA AIDS 2019) in Durban, South Africa, on Thursday, June 13th. The session, which included presentations on the primary analysis, was recorded and can be viewed on YouTube here.
Include in home page features rotation
Off

ECHO Study Factsheet

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label randomised clinical trial comparing three highly effective, reversible methods of contraception — a progestogen-only injectable called depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.Read this fact sheet for more about the ECHO study.
Include in home page features rotation
Off

Exogenous oestrogen inhibits genital transmission of cell-associated HIV-1 in DMPA-treated humanized mice

Is the resource available on the Internet?
Yes
Author
Nirk E Quispe Calla, Rodolfo D Vicetti Miguel, Melissa E Glick, Jesse J Kwiek, Janelle M Gabriel, Thomas L Cherpes

HIV affects more women than any other life-threatening infectious agent, and most infections are sexually transmitted. HIV must breach the female genital tract mucosal barrier to establish systemic infection, and clinical studies indicate virus more easily evades this barrier in women using depot-medroxyprogesterone acetate (DMPA) and other injectable progestins for contraception.

Include in home page features rotation
Off

Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial

Is the resource available on the Internet?
Yes
Author
G Justus Hofmeyr, Mandisa Singata-Madliki, Theresa A Lawrie, Eduardo Bergel, Marleen Temmerman

Background Evidence from observational studies suggests an increased risk of HIV acquisition among women using depot medroxyprogesterone acetate (DMPA) contraception.

Include in home page features rotation
Off

Webinar: New Data, New Questions: An Update on Hormonal Contraception and HIV

Venue
Webinar

AVAC, in collaboration with ICW East Africa, is pleased to invite you to a webinar on the most recent data regarding hormonal contraception and HIV. We hope you will join us on Friday, September 16 at 10 AM East Coast US / 4 PM South Africa / 5 PM East Africa (to confirm the time in your area visit www.timeanddate.com). 

Include in home page features rotation
Off

Most contraceptives not linked to HIV infection, but Depo-Provera may raise risk

Is the resource available on the Internet?
Yes
Author
Liz Highleyman

Over the years studies have produced conflicting evidence about the link between hormonal contraception – especially DMPA, a long-acting progesterone-only injectable – and women's risk of HIV infection.

Include in home page features rotation
Off
Subscribe to DMPA